EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model

Filip Stanicic, Vladimir Zah iD, Dimitrije Grbic, Debra De Angelo

PLOS ONE · 12.11.2024 · 19 (11) · e0313569

DOI: 10.1371/journal.pone.0313569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 12.11.2024. Verfasst von Filip Stanicic und 3 weiteren Autor:innen. Beteiligte Einrichtung: HEOR Department, ZRx Outcomes Research Inc., Mississauga, Ontario, Canada. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine, Models, Economic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lykos Therapeutics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) compared to placebo with therapy (PT) in US healthcare settings.

Methods

A health state-transition model was used to analyze the cost-effectiveness of MDMA-AT for treating patients with chronic PTSD of moderate or higher severity. Both treatment arms consisted of 3 preparation (90-min), 3 interventional (8-h), and 9 integration (90-min) sessions, lasting ~4 months total. All sessions included psychotherapy, with interventional also including MDMA or placebo. After receiving treatment, patients were distributed across health states of No PTSD (not meeting PTSD diagnostic criteria), Non-Severe PTSD (treatment responders), Severe PTSD (treatment non-responders), and death. Each state had unique healthcare costs and utilities sourced from real-world data analysis and patient data from MDMA-AT clinical trials (including long-term follow-up). The base-case analysis considered the payer’s perspective with a 5-year horizon, 3.5% annual cost and effect discounts, and an assumed MDMA medication price of $12,000 per session. Trial-derived utilities and US life tables mortality data were used to calculate quality-adjusted life years (QALY). The main outcome was an incremental cost-effectiveness ratio (ICER) with a $150,000 willingness-to-pay (WTP) threshold.

Results

The base-case ICER was $83,845 per QALY. Total direct costs were $64,745 in the MDMA-AT and $33,132 in the PT arms ($31,613 increment). The costs of intervention were $48,376 for MDMA-AT and $12,376 for PT. The highest MDMA medication cost to fit under the WTP threshold was $20,314 per session. Costs related to PTSD healthcare visits and other PTSD treatments were lower with MDMA-AT than PT (-$2,511 and -$1,877 increments, respectively). Utility benefits were higher in MDMA-AT than PT, with 3.691 and 3.314 QALYs generated over 5 years, respectively (0.377 QALY increment).

Conclusion

These data suggest MDMA-AT may be a cost-effective treatment compared to PT for patients with chronic PTSD of moderate or higher severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisStress Disorders, Post-TraumaticN-Methyl-3,4-methylenedioxyamphetamineModels, EconomicHumansQuality-Adjusted Life YearsMaleSeverity of Illness IndexChronic DiseaseFemale

Substanzen

N-Methyl-3,4-methylenedioxyamphetamine

Autor:innen und Institutionen

  • HEOR Department, ZRx Outcomes Research Inc., Mississauga, Ontario, Canada.
  • Medical Affairs Department, Lykos Therapeutics, San Jose, California, United States of America.

ORCID-Profile: Vladimir Zah

Förderung

  • Lykos Therapeutics Inc.

Zitieren

APA

Stanicic, F., Zah, V., Grbic, D., & De Angelo, D. (2024). Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model. PLOS ONE, 19(11), e0313569. https://doi.org/10.1371/journal.pone.0313569

Vancouver

Stanicic F, Zah V, Grbic D, De Angelo D. Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model. PLOS ONE. 2024;19(11):e0313569. doi:10.1371/journal.pone.0313569

BibTeX
@article{Stanicic2024,
  author = {Stanicic, Filip and Zah, Vladimir and Grbic, Dimitrije and De Angelo, Debra},
  title = {Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {11},
  pages = {e0313569},
  doi = {10.1371/journal.pone.0313569}
}
Kostenlos starten →